Methods for the treatment of her2 amplified cancer

Abstract

Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.

What is claimed is: 
     
         1 . A method for treating HER2 amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method of  claim 1 , wherein the HER2-amplified breast cancer is metastatic. 
     
     
         3 . The method of  claim 1 , wherein the HER2-amplified breast cancer is refractory to a treatment of trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, or MM-111. 
     
     
         4 . The method of  claim 1 , wherein the HER2-amplified breast cancer has a HER2:CEP17 ratio of 2.2-4.0 or >4.0. 
     
     
         5 . The method of  claim 1 , further comprising co-administering an additional therapeutic agent. 
     
     
         6 . The method of  claim 5 , wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent. 
     
     
         7 . The method of  claim 6 , wherein the anti-HER2 therapeutic agent is selected from the group consisting of: trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-111. 
     
     
         8 . The method of  claim 6 , wherein the pan-ErbB inhibitor is selected from the group consisting of: afatinib, neratinib, and dacomitinib. 
     
     
         9 . The method of  claim 6 , wherein the anti-VEGF therapeutic agent is selected from the group consisting of: bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib. 
     
     
         10 . The method of  claim 5 , wherein the additional therapeutic agent is selected from the group consisting of: temsirolimus; paclitaxel; ASLAN001 (also, ARRY-543); vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and 5-FU. 
     
     
         11 . A method for treating HER2 amplified cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one 
       
         
           
           
               
               
           
         
       
     
     
         12 . The method of  claim 11 , wherein the HER2-amplified cancer is selected from the group consisting of: breast, colon, endometrial, cervical, urothelial, lung (including, non-small cell lung cancer), ovarian, gastric, gastroesophageal junction (GEJ), head and neck, biliary tract, prostate, and pancreatic cancer. 
     
     
         13 . The method of  claim 11 , wherein the HER2-amplified cancer is metastatic. 
     
     
         14 . The method of  claim 11 , wherein the HER2-amplified cancer has a HER2:CEP17 ratio of 2.2-4.0 or >4.0. 
     
     
         15 . The method of  claim 11 , wherein the HER2-amplified cancer is refractory to a treatment of trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, or MM-111. 
     
     
         16 . The method of  claim 11 , further comprising co-administering an additional therapeutic agent. 
     
     
         17 . The method of  claim 16 , wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent. 
     
     
         18 . The method of  claim 17 , wherein the anti-HER2 therapeutic agent is selected from the group consisting of: trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-111. 
     
     
         19 . The method of  claim 17 , wherein the pan-ErbB inhibitor is selected from the group consisting of: afatinib, neratinib, and dacomitinib. 
     
     
         20 . The method of  claim 17 , wherein the anti-VEGF therapeutic agent is selected from the group consisting of: bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib. 
     
     
         21 . The method of  claim 16 , wherein the additional therapeutic agent is selected from the group consisting of: temsirolimus; paclitaxel; ASLAN001 (also, ARRY-543); vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and 5-FU.